RAMUCIRUMAB VEGE RECEPTOR-2

ANTAGONIST




The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

This document was commissioned by Lilly Medical and is intended to be used by HCPs for medical, scientific, and educational purposes.

> W-OTHR-US-DEL-1046 11/2023 PRINTED IN USA © 2023 Lilly USA, LLC. All rights reserved.





TARGET

Angiogenesis is a tightly regulated, multiple-step process, which results in the formation of new blood vessels from preexisting vasculature and is an important component in the development and progression of malignant disease. Signaling by vascular endothelial growth factor (VEGF) receptor-2 in endothelial cells plays a role in inducing normal and pathologic angiogenesis and is activated by binding of ligands VEGF-A, VEGF-C, and VEGF-D.¹⁻³

MOLECULE

Ramucirumab is a human IgG1 monoclonal antibody receptor antagonist that has been shown in vitro to bind to and block the activation of VEGF receptor-2 by preventing the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D.^{4,5}

CLINICAL DEVELOPMENT

Ramucirumab is being investigated in clinical trials in patients with non-small cell lung cancer or pediatric sarcoma

References: 1. Adams RH, Alitalo K. Nat Rev Mol Cell Biol. 2007;8(6):464-478. 2. Hicklin DJ, Ellis LM. J Clin Oncol. 2005;23(5):1011-1027. 3. Olsson AK, et al. Nat Rev Mol Cell Biol. 2006;7(5):359-371. 4. Lu D, et al. J Biol Chem. 2003;278(44):43496-43507. 5. Zhu Z, et al. Leukemia. 2003;17(3):604-611.

Adams RH and Alitalo K¹; Hicklin DJ and Ellis LM²

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

This document was commissioned by Lilly Medical and is intended to be used by HCPs for medical, scientific, and educational purposes. VV-OTHR-US-DEL-1046 11/2023 PRINTED IN USA © 2023 Lilly USA, LLC. All rights reserved. - 3

ACTIVE TRIALS CURRENTLY NOT ENROLLING

[NCT02411448] Lung Cancer

RELAY: A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC

[NCT04145349] Pediatric Cancer

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

This document was commissioned by Lilly Medical and is intended to be used by HCPs for medical, scientific, and educational purposes.



Pipeline information is current through November 2, 2023. W-OTHR-US-DEL-1046 11/2023 PRINTED IN USA © 2023 Lilly USA, LLC. All rights reserved.

Printed on post-consumer recycled paper.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.